Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd (symbol: CGEN) is a cutting-edge drug discovery company specializing in developing therapeutic proteins and monoclonal antibodies to meet critical needs in immunology and oncology. By leveraging a sophisticated infrastructure of proprietary scientific insights, predictive platforms, algorithms, and machine learning systems, Compugen excels in in silico (computer-based) prediction and selection of promising product candidates for its pipeline program.
Compugen's business model is robust and diversified, encompassing partnerships and collaborations for the further development and commercialization of its product candidates. These collaborations typically offer milestone payments and royalties on product sales, providing Compugen with multiple revenue streams. The company's U.S. subsidiary, based in South San Francisco, focuses on developing monoclonal antibodies.
At the core of Compugen's operations is its clinical-stage therapeutic discovery and development efforts, primarily in cancer immunotherapy. Its comprehensive immuno-oncology pipeline includes four clinical-stage programs, each targeting immune checkpoints discovered through computational methods. Notable programs include COM701, COM902, and bapotulimab. These programs are designed to tackle various mechanisms of immune resistance, with a particular focus on myeloid targets.
Recent achievements highlight Compugen's forward momentum. The company announced it would release its fourth quarter and full-year 2023 financial results on March 5, 2024. Compugen's President and CEO, Anat Cohen-Dayag, emphasized the company's strong financial footing, collaboration successes, and the anticipated catalytic milestones in 2024.
Key partnerships enhance Compugen’s clinical progress. For instance, the company has a license agreement with Gilead Sciences for COM503, a first-in-class antibody program against IL-18 binding protein. This agreement includes a $60 million upfront payment and a $30 million milestone payment upon IND clearance.
Another significant partnership is with AstraZeneca, which is advancing a PD-1/TIGIT bispecific antibody derived from Compugen's COM902 into Phase 3 development. This program, rilvegostomig, targets biliary tract cancer and nonsquamous non-small cell lung cancer. These collaborations underscore the extensive potential and validation of Compugen's computational discovery platform.
Compugen's financial health is robust, with a reported cash balance of $101.3 million as of March 31, 2024, ensuring operational funding into 2027. The company has demonstrated prudent financial management, achieving net revenues and reducing operational losses over time.
Headquartered in Israel, with additional offices in San Francisco, Compugen is listed on both Nasdaq and the Tel Aviv Stock Exchange, making it a prominent player in the biotech sector. For investors and stakeholders, Compugen represents a beacon of innovation and potential in cancer immunotherapy.
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company, announced its participation in two upcoming investor conferences. The Jefferies Healthcare Conference will take place in New York City on June 8, 2022, with a fireside chat scheduled for 1:30 PM ET. The JMP Securities Life Sciences Conference is also in New York City on June 15, 2022, at 9:00 AM ET. Live webcasts of both events will be available on Compugen's Investor Relations website.
Compugen Ltd. (CGEN) reported its Q1 2022 financial results, noting a cash balance of $107 million, down from $118 million in Q4 2021. The company continues to execute on its clinical strategy with ongoing Phase 1 studies for COM701 and COM902, aiming for initial data in Q4 2022 related to MSS CRC. COM902 demonstrated a disease control rate of 50%, while R&D expenses were $7.2 million, slightly down year-over-year. Despite a net loss of $9.7 million, the company expects sufficient funds to sustain operations into 2024.
Compugen Ltd. (Nasdaq: CGEN) announced that CFO and COO Ari Krashin will depart the company in August 2022 to pursue other interests. His departure is unrelated to the company's operations or policies. Compugen is a clinical-stage cancer immunotherapy firm known for its predictive computational discovery capabilities, developing drug candidates like COM701 and COM902, targeting various solid tumors. The company maintains partnerships with Bayer and AstraZeneca for its therapeutic programs. Compugen is headquartered in Israel with additional offices in South San Francisco.
Compugen Ltd. (CGEN) will announce its first quarter 2022 financial results on May 16, 2022, before U.S. markets open. The company will not hold a conference call post-release. Additionally, Compugen plans to present a corporate update at two healthcare conferences in June 2022, with more details to follow. Compugen focuses on developing cancer immunotherapies and is currently advancing two product candidates: COM701 and COM902, both in Phase 1 studies.
Compugen Ltd. (CGEN) presented its research on exploring the immune-tumor microenvironment at the Keystone Symposium on March 21, 2022. Using high-resolution single-cell spatial transcriptomics, Compugen revealed insights into immune cell interactions and highlighted the role of the DNAM-1 pathway, including PVRIG, which could help combat immunotherapy resistance. The company leverages a cloud-based computational platform that integrates omics data for drug discovery, enhancing its drug development capabilities in cancer immunotherapy.
Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company, will present insights on the immune-tumor microenvironment at the Keystone Symposium on Cancer Immunotherapy, scheduled for March 20-24, 2022, in British Columbia, Canada. The oral presentation is set for March 21, 2022, titled "Exploring the immune-tumor microenvironment using high resolution single-cell spatial transcriptomics." A poster will also be presented on March 22, 2022, showcasing further findings. More details and the presentation will be available on Compugen's website.
Compugen Ltd. (NASDAQ: CGEN) announced its participation in the Oppenheimer 32nd Annual Global Healthcare Conference on March 16, 2022, at 11:20 am ET. The presentation will be accessible via live webcast on Compugen's Investor Relations page, with a replay available afterward. Compugen specializes in cancer immunotherapy and has developed key products such as COM701 and COM902, both in Phase 1 clinical trials. The company is headquartered in Israel and has a strong pipeline of immuno-oncology programs targeting various immune resistance mechanisms.
Compugen (CGEN) announced new research indicating that targeting PVRIG and TIGIT may improve treatment options for multiple myeloma. Conducted with Dr. James Berenson, the study highlights the expression of the PVRIG/TIGIT pathway in the bone marrow of patients. Details will be presented at the AACR annual meeting from April 8-13, 2022, in New Orleans, with the poster presentation scheduled for April 10, 2022, under number 4934. The data suggest combining TIGIT and PVRIG inhibitors could offer new therapeutic pathways for patients.
Compugen Ltd. (Nasdaq: CGEN) announced the appointment of Mathias Hukkelhoven, Ph.D., to its Board of Directors effective March 1, 2022. Dr. Hukkelhoven brings extensive experience in immuno-oncology and regulatory affairs, having previously served at Bristol Myers Squibb. His background includes involvement in breakthrough drug designations and regulatory strategies. This strategic addition aims to bolster Compugen's innovative pipeline targeting cancer treatments. Dr. Jean-Pierre Bizzari will retire from the board on the same date, concluding his tenure at the company.
Compugen Ltd. (Nasdaq: CGEN) reported its fourth quarter and full-year 2021 financial results, highlighting significant progress in cancer immunotherapy. The company emphasized advancements in its DNAM-1 axis research and early anti-tumor signals from its drugs, COM701 and COM902. Key financials included no revenue for Q4 2021, a total of $6 million for the year, and a net loss of approximately $34.2 million. The company expanded its collaboration with Bristol Myers Squibb with a $20 million investment, while cash reserves totaled about $118 million, expected to fund operations into 2024.
FAQ
What is the current stock price of Compugen (CGEN)?
What is the market cap of Compugen (CGEN)?
What is Compugen Ltd's primary business focus?
What makes Compugen unique in the biotech industry?
Who are Compugen's key partners?
What are some of Compugen's notable products?
What recent financial milestones has Compugen achieved?
Where is Compugen Ltd headquartered?
On which stock exchanges are Compugen's shares listed?
What are some of Compugen's recent achievements?
What is the significance of Compugen’s computational discovery platform?
What is Compugen's approach to advancing its pipeline?
